CardioExchange Archive

February 2nd, 2012

Study Explores Role of Periprocedural Dabigatran in AF Ablation

Larry Husten, PHD

As dabigatran becomes more widely used in AF patients, electrophysiologists are trying to figure out how to handle anticoagulation in patients taking the drug and for whom AF ablation is planned. In a new study published in the Journal of the American College of Cardiology, Dhanunjaya Lakkireddy and colleagues report on a multicenter, observational study of 290 patients […]

---

October 28th, 2011

FDA Advisory Panel Votes 8-2 Against Approval of Medtronic AF Ablation System

Larry Husten, PHD

An FDA advisory panel has recommended against approval of Medtronic’s Ablation Frontiers Cardiac Ablation System for the treatment of symptomatic, drug refractory, persistent atrial fibrillation (AF) or longstanding persistent AF of up to four years in duration. In an 8-2 vote, members of the Circulatory System Devices Panel said that the risks of the device outweighed its […]

---

January 5th, 2011

Study Finds Mixed Long-Term Results for AF Catheter Ablation

Larry Husten, PHD

Long-term results after catheter ablation for AF are decidedly mixed, according to the longest study yet to follow patients after the procedure. In a report in the Journal of the American College of Cardiology, Rukshen Weerasooriya and colleagues followed 100 patients treated at a French hospital for 5 years. After a single procedure, the rates of arrhythmia-free survival […]

---